We are live on ! Find out more
SVA

Sinovac Biotech, Ltd
SVA

Delisted

SVA was delisted on the 22nd of February, 2019.

Back to rankings

33 hedge funds and large institutions have $47.2M invested in Sinovac Biotech, Ltd in 2013 Q2 according to their latest regulatory filings, with 33 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

197% more call options, than puts

Call options by funds: $386K | Put options by funds: $130K

Holders
33
Holders Change
+33
Holders Change %
–
% of All Funds
1.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
33
Increased
–
Reduced
–
Closed
–
Calls
$386K
Puts
$130K
Net Calls
+$256K
Net Calls Change
+$256K

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$11M +$10.4M +2,794,071 New
DSA
2
Davis Selected Advisers
Arizona
$10.3M +$9.78M +2,627,231 New
O
3
OrbiMed
New York
$7.41M +$7.01M +1,884,200 New
Fidelity International
4
Fidelity International
Bermuda
$4.2M +$3.98M +1,069,500 New
VAM
5
Visium Asset Management
New York
$3.93M +$3.72M +1,000,000 New
PRCM
6
Pine River Capital Management
Minnesota
$3.33M +$3.15M +846,554 New
BFA
7
BlackRock Fund Advisors
California
$2M +$1.89M +508,927 New
Renaissance Technologies
8
Renaissance Technologies
New York
$1.55M +$1.46M +393,600 New
Invesco
9
Invesco
Georgia
$815K +$772K +207,488 New
Deutsche Bank
10
Deutsche Bank
Germany
$738K +$701K +188,345 New
Morgan Stanley
11
Morgan Stanley
New York
$480K +$454K +122,126 New
California Public Employees Retirement System
12
California Public Employees Retirement System
California
$298K +$282K +75,900 New
TC
13
TFS Capital
Pennsylvania
$192K +$182K +48,914 New
ARTA
14
A.R.T. Advisors
New York
$169K +$161K +43,175 New
BIT
15
BlackRock Institutional Trust
California
$144K +$136K +36,525 New
Millennium Management
16
Millennium Management
New York
$110K +$104K +27,998 New
RCM
17
Rotella Capital Management
Washington
$104K +$98.3K +26,429 New
Citadel Advisors
18
Citadel Advisors
Florida
$88K +$83.1K +22,326 New
TRCT
19
Tower Research Capital (TRC)
New York
$79K +$75.3K +20,225 New
Citigroup
20
Citigroup
New York
$74K +$70.9K +19,052 New
SIM
21
Spark Investment Management
New York
$44K +$42.1K +11,300 New
ProShare Advisors
22
ProShare Advisors
Maryland
$41K +$39.1K +10,498 New
Bank of America
23
Bank of America
North Carolina
$22K +$20.5K +5,499 New
Group One Trading
24
Group One Trading
Illinois
$20K +$18.6K +5,009 New
Creative Planning
25
Creative Planning
Kansas
$18K +$16.7K +4,500 New
1
2

SVA Hedge Fund Activity: Q2 2013 in Review

33 of the 3,064 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q2 2013, worth a combined $47.2M.

Buyers outnumbered sellers: 33 funds opened new SVA positions and 0 closed out — a net gain of 33 holders — while 0 added to existing stakes and 0 trimmed.

  • 33 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $47.2M of Sinovac Biotech, Ltd stock for Q2 2013.
  • 33 funds opened new Sinovac Biotech, Ltd positions in Q2 2013 and 0 closed out, a net change of +33 holders.

Based on aggregated 13F filings for Q2 2013.